Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 and Prevnar 13 Interchangeability in Healthy Infants
NCT03620162Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Oct 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03620162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620162.